Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.45 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 2/20 | 0.44 |
| ▸ | ATR | Q13535 | 7/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 6/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30009053 | 0.79 | ATR (0.59) | AKT2NUDT1PBKATRATRIP | |
| SCHEMBL30008973 | 0.76 | AKT2 (0.54) | AKT2GSK3BALDH1A1NUDT1PBK | |
| SCHEMBL30009365 | 0.75 | AKT2 (0.53) | AKT2GSK3BALDH1A1NUDT1PBK | |
| SCHEMBL30356228 | 0.75 | JAK1 (0.67) | JAK1 | |
| SCHEMBL20918106 | 0.75 | JAK1 (0.67) | JAK1 | |
| SCHEMBL12605440 | 0.73 | AKT2 (0.70) | AKT2GSK3BNUDT1PBK | |
| SCHEMBL18440877 | 0.72 | AKT2 (0.65) | AKT2GSK3BNUDT1PBKAKT1 | |
| SCHEMBL12605530 | 0.72 | AKT2 (0.68) | AKT2GSK3BNUDT1PBK | |
| SCHEMBL2799562 | 0.70 | AKT2 (0.67) | AKT2GSK3BNUDT1PBK | |
| SCHEMBL12696677 | 0.70 | ALDH1A1 (0.43) | AKT2ALDH1A1AKT1ATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | HK INNO.N CORPORATION (KR) | 2022-12-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524968-B2 | Heterocyclic compound as a protein kinase inhibitor | MAP3K20, MAP3K15, MAP3K1 | AKT2 208/4885GSK3B 550/4885ALDH1A1 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.